Twist Bioscience Corp
Close on Oct 19, 2026
- Market cap
- $8.72B
- P/E (TTM)
- –
- Dividend yield
- –
About Twist Bioscience
Biological Products, (No Diagnostic Substances), SIC 2836
Twist Bioscience Corporation is a synthetic biology company that manufactures synthetic DNA using a proprietary silicon chip platform. Its primary offerings comprise synthetic biology tools—such as clonal genes, gene fragments, oligo pools, and IgG proteins—and next-generation sequencing products, including target enrichment panels and library preparation kits. In addition, the company provides biopharma solutions for antibody discovery, optimization, and characterization. It sells products and services to biopharmaceutical companies, diagnostic laboratories, agricultural enterprises, chemical manufacturers, and academic research institutions.
The company serves more than 3,800 customers worldwide across the healthcare, industrial chemicals, academic, and agricultural sectors. Twist Bioscience maintains manufacturing and operations facilities in South San Francisco, California, and Wilsonville, Oregon, supported by commercial personnel and consultants in Europe and Asia. Its principal manufacturing and operational base is located in South San Francisco, California.
Summary of the business section of Twist Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Twist Bioscience Corp
- Headquarters
- South San Francisco, CA
- Address
- 681 Gateway Blvd. 94080
- Phone
- (800) 719-0671
- Website
- twistbioscience.com
- Employees
- 979, Sep 30, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- TWST
- Exchange
- Nasdaq
- IPO date
- Nov 1, 2018
- Shares outstanding
- 63M, Jul 29, 2026
- Public float
- $2.32B, Mar 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1581280
- CUSIP
- 90184D100
- ISIN
- US90184D1000
- LEI
- 549300T23BL59LCOH584
- EIN
- 46-2058888
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Emily M. Leproust | Chief Executive Officer, Director | 616,205 |
| Dennis Cho | See Remarks | 73,303 |
| Paula Green | SVP of Human Resources | 116,720 |
| Robert F. Werner | Chief Accounting Officer | 44,399 |
| Patrick John Finn | President and COO | 210,802 |
| Adam Laponis | Chief Financial Officer | 108,633 |
| Katryn Blake | Director | 17,208 |
| Robert Chess | Director | 63,612 |
| Melissa A. Starovasnik | Director | 22,222 |
| Jan Johannessen | Director | 29,754 |
| Robert P. Ragusa | Director | 28,983 |
| Keith Crandell | Director | 103,618 |
| Nelson Chan | Director | 33,251 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Leproust | $13.78M | $928.13K | $4.80M | $37 | $119 |
| FY2024 Dr. Leproust | $7.62M | $24.98M | $2.68M | $59 | $116 |
| FY2023 Dr. Leproust | $8.00M | $3.22M | $3.09M | $27 | $95 |
| FY2022 Dr. Leproust | $5.92M | -$15.04M | $2.48M | $46 | $90 |
| FY2021 Dr. Leproust | $1.28M | $18.05M | $728.15K | $141 | $120 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had 979 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 9, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 1, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 25, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |